Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease
Open Access
- 21 May 2020
- journal article
- research article
- Published by Elsevier BV in American Heart Journal
- Vol. 226, 60-68
- https://doi.org/10.1016/j.ahj.2020.05.010
Abstract
No abstract availableFunding Information
- Netherlands Heart Institute
- Dutch Heart Foundation
- Dutch Cardiovascular Alliance
- Novartis Pharma BV
- Netherlands Heart Institute
- Dutch Heart Foundation
- Dutch Cardiovascular Alliance
- Novartis Pharma BV
This publication has 36 references indexed in Scilit:
- Angiotensin II Mediates Angiotensin Converting Enzyme Type 2 Internalization and Degradation Through an Angiotensin II Type I Receptor–Dependent MechanismHypertension, 2014
- The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular DiseasesDrug Safety, 2014
- Urinary Angiotensin-Converting Enzyme 2 in Hypertensive Patients May Be Increased by Olmesartan, an Angiotensin II Receptor BlockerAmerican Journal of Hypertension, 2014
- SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical TrialsAnnals of Internal Medicine, 2013
- A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injuryNature Medicine, 2005
- Angiotensin-converting enzyme 2 protects from severe acute lung failureNature, 2005
- Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolismBiochemical Journal, 2004
- Upregulation of Angiotensin-Converting Enzyme 2 After Myocardial Infarction by Blockade of Angiotensin II ReceptorsHypertension, 2004
- Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirusNature, 2003
- Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeThe Lancet, 2003